Neurotech

Neurotech Pharmaceuticals is developing sight-saving therapeutics for the treatment of chronic retinal diseases. NT-501, one of the company’s lead product candidates, is currently in late-stage clinical development for retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (dry AMD). Neurotech’s portfolio of product candidates also includes treatments for wet AMD, including NT-503 that delivers a VEGF antagonist.